Globeimmune, Inc. (OTCMKTS:GBIM – Get Free Report) crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $0.00 and traded as high as $0.0001. Globeimmune shares last traded at $0.00, with a volume of 0 shares changing hands.
Globeimmune Price Performance
About Globeimmune
GlobeImmune, Inc, a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy.
Recommended Stories
- Five stocks we like better than Globeimmune
- Roth IRA Calculator: Calculate Your Potential Returns
- ServiceNow’s $7 Billion Gamble: Panic or Opportunity?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Dell and HP Are Raising Prices—And Investors Should Take Note
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026
Receive News & Ratings for Globeimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globeimmune and related companies with MarketBeat.com's FREE daily email newsletter.
